Stock Scorecard



Stock Summary for Aerie Pharmaceuticals Inc (AERI)

Total Score

10 out of 29

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for AERI

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AERI

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AERI

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for AERI

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Financial Details for AERI

Company Overview

Company Name Aerie Pharmaceuticals Inc
Country USA
Description Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of world-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. The company is headquartered in Durham, North Carolina.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2022
Next Earnings Date 2/22/2023

Stock Price History

Last Day Price 15.25
Last Day Volume 0
Average Daily Volume 595,776
52-Week High 15.37
52-Week Low 4.81
Last Price to 52 Week Low 217.05 %

Valuation Measures

Trailing PE 0.00
Industry PE 220.22
Sector PE 93.33
5-Year Average PE -7.65
Free Cash Flow Ratio 4.37
Industry Free Cash Flow Ratio 8.54
Sector Free Cash Flow Ratio 37.81
Book Value Per Share Most Recent Quarter 0.51
Price to Book Ratio 34.26
Industry Price to Book Ratio 11.44
Sector Price to Book Ratio 15.40
Price to Sales Ratio Twelve Trailing Months 3.52
Industry Price to Sales Ratio Twelve Trailing Months 42.99
Sector Price to Sales Ratio Twelve Trailing Months 25.28

Share Statistics

Total Shares Outstanding 49,417,400
Market Capitalization 753,615,350
Institutional Ownership 0.00 %

Dividends

Ex-Dividend Date
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00 %
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Average Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio 0.00 %

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth 59.14 %
Reported EPS Past Year -1.25
Reported EPS Prior Year -1.02
Net Income Twelve Trailing Months -36,555,000
Net Income Past Year -74,810,000
Net Income Prior Year -183,101,000
Quarterly Revenue Growth YOY 23.30 %
5-Year Revenue Growth 256.76 %

Balance Sheet

Total Cash Per Share 3.49
Total Cash Most Recent Quarter 172,500,000
Total Cash Past Year 139,801,000
Total Cash Prior Year 240,364,000
Net Cash Position Most Recent Quarter -140,088,000
Net Cash Position Past Year -94,726,000
Long Term Debt Past Year 234,527,000
Long Term Debt Prior Year 210,373,000
Total Debt Most Recent Quarter 312,588,000
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Current Ratio Most Recent Quarter 2.27
Total Stockholder Equity Past Year 48,000
Total Stockholder Equity Prior Year 23,968,000
Total Stockholder Equity Most Recent Quarter 49,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

MACD 0.06
MACD Signal 0.08
20-Day Bollinger Lower Band 7.40
20-Day Bollinger Middle Band 13.34
20-Day Bollinger Upper Band 19.28
Beta -0.06
RSI 69.92
50-Day SMA 9.66
200-Day SMA 17.51

System

Modified 11/30/2022 10:26:14 PM